367 related articles for article (PubMed ID: 27070304)
21. Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.
Zuluaga Toro T; Hsieh FH; Bodo J; Dong HY; Hsi ED
Br J Haematol; 2007 Oct; 139(1):31-40. PubMed ID: 17662084
[TBL] [Abstract][Full Text] [Related]
22. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.
Bonadonna P; Perbellini O; Passalacqua G; Caruso B; Colarossi S; Dal Fior D; Castellani L; Bonetto C; Frattini F; Dama A; Martinelli G; Chilosi M; Senna G; Pizzolo G; Zanotti R
J Allergy Clin Immunol; 2009 Mar; 123(3):680-6. PubMed ID: 19135713
[TBL] [Abstract][Full Text] [Related]
23. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow.
Johnson MR; Verstovsek S; Jorgensen JL; Manshouri T; Luthra R; Jones DM; Bueso-Ramos CE; Medeiros LJ; Huh YO
Mod Pathol; 2009 Jan; 22(1):50-7. PubMed ID: 19116630
[TBL] [Abstract][Full Text] [Related]
24. A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.
Jordan JH; Fritsche-Polanz R; Sperr WR; Mitterbauer G; Födinger M; Schernthaner GH; Christian Bankl H; Gebhart W; Chott A; Lechner K; Valent P
Leuk Res; 2001 Jul; 25(7):627-34. PubMed ID: 11377687
[TBL] [Abstract][Full Text] [Related]
25. [Mastocytosis: when should it be considered?].
Comte-Perret S; Bart PA; Spertini F; Leimgruber A
Rev Med Suisse; 2009 Apr; 5(199):837-42. PubMed ID: 19441750
[TBL] [Abstract][Full Text] [Related]
26. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.
Brockow K; Jofer C; Behrendt H; Ring J
Allergy; 2008 Feb; 63(2):226-32. PubMed ID: 18186813
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.
Valent P; Escribano L; Parwaresch RM; Schemmel V; Schwartz LB; Sotlar K; Sperr WR; Horny HP
Int Arch Allergy Immunol; 1999 Sep; 120(1):1-7. PubMed ID: 10529583
[TBL] [Abstract][Full Text] [Related]
28. Serum tryptase and SCORMA (SCORing MAstocytosis) Index as disease severity parameters in childhood and adult cutaneous mastocytosis.
Heide R; van Doorn K; Mulder PG; van Toorenenbergen AW; Beishuizen A; de Groot H; Tank B; Oranje AP
Clin Exp Dermatol; 2009 Jun; 34(4):462-8. PubMed ID: 19077102
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome.
Sonneck K; Florian S; Müllauer L; Wimazal F; Födinger M; Sperr WR; Valent P
Int Arch Allergy Immunol; 2007; 142(2):158-64. PubMed ID: 17057414
[TBL] [Abstract][Full Text] [Related]
31. Mastocytosis.
Brockow K; Metcalfe DD
Chem Immunol Allergy; 2010; 95():110-124. PubMed ID: 20519885
[TBL] [Abstract][Full Text] [Related]
32. Anesthesia in children with mastocytosis--a case based review.
Ahmad N; Evans P; Lloyd-Thomas AR
Paediatr Anaesth; 2009 Feb; 19(2):97-107. PubMed ID: 19207896
[TBL] [Abstract][Full Text] [Related]
33. [Mastocytosis and anaesthesia].
Dewachter P; Mouton-Faivre C; Cazalaà JB; Carli P; Lortholary O; Hermine O
Ann Fr Anesth Reanim; 2009 Jan; 28(1):61-73. PubMed ID: 19097849
[TBL] [Abstract][Full Text] [Related]
34. [Current concepts and treatment advances in systemic mastocytosis].
Georgin-Lavialle S; Barete S; Suarez F; Lepelletier Y; Bodemer C; Dubreuil P; Lortholary O; Hermine O
Rev Med Interne; 2009 Jan; 30(1):25-34. PubMed ID: 18406017
[TBL] [Abstract][Full Text] [Related]
35. Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.
Rydz A; Lange M; Ługowska-Umer H; Sikorska M; Nowicki RJ; Morales-Cabeza C; Alvarez-Twose I
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338679
[TBL] [Abstract][Full Text] [Related]
36. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
Hahn HP; Hornick JL
Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
[TBL] [Abstract][Full Text] [Related]
37. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
Akin C
J Mol Diagn; 2006 Sep; 8(4):412-9. PubMed ID: 16931579
[TBL] [Abstract][Full Text] [Related]
38. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
39. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP
Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815
[TBL] [Abstract][Full Text] [Related]
40. Mastocytosis in children: a protocol for management.
Heide R; Beishuizen A; De Groot H; Den Hollander JC; Van Doormaal JJ; De Monchy JG; Pasmans SG; Van Gysel D; Oranje AP;
Pediatr Dermatol; 2008; 25(4):493-500. PubMed ID: 18789103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
